Search

Your search keyword '"MCARTHUR, GRANT A."' showing total 643 results
Start Over Author "MCARTHUR, GRANT A." Language english
643 results on '"MCARTHUR, GRANT A."'

4. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

Author

Ertl, Carolin, Ruf, Theresa, Mentzer, Dirk, Kong, Mingzi, Kramer, Rafaela, Bergwelt-Baildon, Michael von, Subklewe, Marion, Tomsitz, Dirk, Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen, Lebbé, Celeste, Long, Georgina V., McArthur, Grant, Neilan, Tomas G., Ribas, Antoni, Robert, Caroline, Schadendorf, Dirk, Zimmer, Lisa, Eigentler, Thomas, Grabbe, Stephan, Forschner, Andrea, Kähler, Katharina C., Milani, Valeria, Pföhler, Claudia, Hassel, Jessica, Gutzmer, Ralf, Loquai, Carmen, Routy, Bertrand, Furness, Andrew J.S., Blank, Christian, Wolchok, Jedd D., French, Lars E., Hauschild, Axel, and Heinzerling, Lucie

Published
2024
Full Text
View/download PDF

5. A tailored approach to horizon scanning for cancer medicines

Author

Soon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J., Gibbs, Peter, McArthur, Grant A., Franchini, Fanny, and IJzerman, Maarten

Published
2023
Full Text
View/download PDF

6. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Author

Ascierto, Paolo A, Stroyakovskiy, Daniil, Gogas, Helen, Robert, Caroline, Lewis, Karl, Protsenko, Svetlana, Pereira, Rodrigo P, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev, Zhukova, Natalia, Schachter, Jacob, Yan, Yibing, Caro, Ivor, Hertig, Christian, Xue, Cloris, Kusters, Lieke, McArthur, Grant A, and Gutzmer, Ralf

Published
2023
Full Text
View/download PDF

11. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

Author

Smith, Lorey K., Parmenter, Tiffany, Kleinschmidt, Margarete, Kusnadi, Eric P., Kang, Jian, Martin, Claire A., Lau, Peter, Patel, Riyaben, Lorent, Julie, Papadopoli, David, Trigos, Anna, Ward, Teresa, Rao, Aparna D., Lelliott, Emily J., Sheppard, Karen E., Goode, David, Hicks, Rodney J., Tiganis, Tony, Simpson, Kaylene J., Larsson, Ola, Blythe, Benjamin, Cullinane, Carleen, Wickramasinghe, Vihandha O., Pearson, Richard B., and McArthur, Grant A.

Published
2022
Full Text
View/download PDF

12. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Author

Scolyer, Richard A., Atkinson, Victoria, Gyorki, David E., Lambie, Duncan, O'Toole, Sandra, Saw, Robyn P.M., Amanuel, Benhur, Angel, Christopher M., Button-Sloan, Alison E., Carlino, Matteo S., Ch'ng, Sydney, Colebatch, Andrew J., Daneshvar, Dariush, Pires da Silva, Inês, Dawson, Tamara, Ferguson, Peter M., Foster-Smith, Erwin, Fox, Stephen B., Gill, Anthony J., Gupta, Ruta, Henderson, Michael A., Hong, Angela M., Howle, Julie R., Jackett, Louise A., James, Craig, Lee, C. Soon, Lochhead, Alistair, Loh, Daphne, McArthur, Grant A., McLean, Catriona A., Menzies, Alexander M., Nieweg, Omgo E., O'Brien, Blake H., Pennington, Thomas E., Potter, Alison J., Prakash, Saurabh, Rawson, Robert V., Read, Rebecca L., Rtshiladze, Michael A., Shannon, Kerwin F., Smithers, B. Mark, Spillane, Andrew J., Stretch, Jonathan R., Thompson, John F., Tucker, Paul, Varey, Alexander H.R., Vilain, Ricardo E., Wood, Benjamin A., and Long, Georgina V.

Published
2022
Full Text
View/download PDF

13. Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery.

Author

Smith, Kortnye, O'Haire, Sophie, Markman, Benjamin, Gan, Hui K., O'Byrne, Kenneth, Millward, Michael, Tran, Ben, Solomon, Benjamin J., Scott, Clare, Kee, Damien, McArthur, Grant, Fellowes, Andrew, Khoung-Quang, Dong Anh K., Ekert, Paul, James, Paul, Xu, Huiling, Martyn, Melissa, Lynch, Elly, Weerasuriya, Rona, and Gaff, Clara

Subjects
CANCER patients, PATIENT experience, PATIENTS' attitudes, CANCER patient care, PATIENT preferences
Abstract

PURPOSE: Despite increasing evidence of benefit supporting complex genomic sequencing (CGS) in personalizing cancer therapy, its widespread uptake remains limited. METHODS: This mixed-methods, prospective cross-institutional demonstration study was designed to evaluate implementation of CGS in the care of patients with advanced cancer. DNA sequencing was undertaken on formalin-fixed paraffin-embedded tumor and matched blood was completed with the Peter MacCallum Cancer Centre Comprehensive Cancer Panel; 391 genes via central laboratory. Oncologists performed consent and result delivery. Patients completed pre- and post-test surveys, including validated and study-specific questions and, if eligible, semistructured interviews. Qualitative interviews were undertaken with study clinicians to evaluate processes. RESULTS: One hundred ninety-nine (63%) had ≥1 finding with the potential to affect management, including 172 (55%) whose finding could affect their treatment options, 25 (8%) whose test led to the resolution of diagnostic ambiguity, and 49 (16%) with a pathogenic germline variant. In 6-month follow-up, 50 (16%) participants had their subsequent therapy changed on the basis of their CGS results. Two hundred ninety-three (88% of adult patients) completed surveys at three time points. At consent, patients cited multifaceted value in testing, showed good understanding of basic concepts, but most (69%) overestimated the likelihood of result-led change. Post-test patients remained consistently satisfied with accessing CGS. 21% struggled with understanding results but there were low levels of decisional regret after participation (89% had nil/mild regret). Clinicians cited collaboration and communication as critical to delivery. CONCLUSION: Patients undergoing CGS are generally satisfied and place value on its use beyond potential therapeutic benefit. Our results suggest that to improve test utility and delivery of CGS with value to patients and investing institutions, focus must be placed on addressing the additional barriers to its wider implications including efforts to improve process efficiencies, clinician genomic literacy, and decision-making support. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci.

Author

Cameron, Donald P., Sornkom, Jirawas, Alsahafi, Sameerh, Drygin, Denis, Poortinga, Gretchen, McArthur, Grant A., Hein, Nadine, Hannan, Ross, and Panov, Konstantin I.

Subjects
DNA repair, RIBOSOMAL DNA, RNA polymerases, DNA damage, GENETIC transcription
Abstract

While genotoxic chemotherapeutic agents are among the most effective tools to combat cancer, they are often associated with severe adverse effects caused by indiscriminate DNA damage in non-tumor tissue as well as increased risk of secondary carcinogenesis. This study builds on our previous work demonstrating that the RNA Polymerase I (Pol I) transcription inhibitor CX-5461 elicits a non-canonical DNA damage response and our discovery of a critical role for Topoisomerase 2α (Top2α) in the initiation of Pol I-dependent transcription. Here, we identify Top2α as a mediator of CX-5461 response in the murine Eµ-Myc B lymphoma model whereby sensitivity to CX-5461 is dependent on cellular Top2α expression/activity. Most strikingly, and in contrast to canonical Top2α poisons, we found that the Top2α-dependent DNA damage induced by CX-5461 is preferentially localized at the ribosomal DNA (rDNA) promoter region, thereby highlighting CX-5461 as a loci-specific DNA damaging agent. This mechanism underpins the efficacy of CX-5461 against certain types of cancer and can be used to develop effective non-genotoxic anticancer drugs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Correction: Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Author

AbuHammad, Shatha, Cullinane, Carleen, Martin, Claire, Bacolas, Zoe, Ward, Teresa, Chen, Huiqin, Slater, Alison, Ardley, Kerry, Kirby, Laura, Chan, Keefe T., Brajanovski, Natalie, Smith, Lorey K., Rao, Aparna D., Lelliott, Emily J., Kleinschmidt, Margarete, Vergara, Ismael A., Papenfuss, Anthony T., Lau, Peter, Ghosh, Prerana, Haupt, Sue, Haupt, Ygal, Sanij, Elaine, Poortinga, Gretchen, Pearson, Richard B., Falk, Hendrik, Curtis, David J., Stupple, Paul, Devlin, Mark, Street, Ian, Davies, Michael A., McArthur, Grant A., and Sheppard, Karen E.

Published
2020

18. Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Author

AbuHammad, Shatha, Cullinane, Carleen, Martin, Claire, Bacolas, Zoe, Ward, Teresa, Chen, Huiqin, Slater, Alison, Ardley, Kerry, Kirby, Laura, Chan, Keefe T., Brajanovski, Natalie, Smith, Lorey K., Rao, Aparna D., Lelliott, Emily J., Kleinschmidt, Margarete, Vergara, Ismael A., Papenfuss, Anthony T., Lau, Peter, Ghosh, Prerana, Haupt, Sue, Haupt, Ygal, Sanij, Elaine, Poortinga, Gretchen, Pearson, Richard B., Falk, Hendrik, Curtis, David J., Stupple, Paul, Devlin, Mark, Street, Ian, Davies, Michael A., McArthur, Grant A., and Sheppard, Karen E.

Published
2019

19. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling

Author

Vergara, Ismael A., Mintoff, Christopher P., Sandhu, Shahneen, McIntosh, Lachlan, Young, Richard J., Wong, Stephen Q., Colebatch, Andrew, Cameron, Daniel L., Kwon, Julia Lai, Wolfe, Rory, Peng, Angela, Ellul, Jason, Dou, Xuelin, Fedele, Clare, Boyle, Samantha, Arnau, Gisela Mir, Raleigh, Jeanette, Hatzimihalis, Athena, Szeto, Pacman, Mooi, Jennifer, Widmer, Daniel S., Cheng, Phil F., Amann, Valerie, Dummer, Reinhard, Hayward, Nicholas, Wilmott, James, Scolyer, Richard A., Cho, Raymond J., Bowtell, David, Thorne, Heather, Alsop, Kathryn, Cordner, Stephen, Woodford, Noel, Leditschke, Jodie, O’Brien, Patricia, Dawson, Sarah-Jane, McArthur, Grant A., Mann, Graham J., Levesque, Mitchell P., Papenfuss, Anthony T., and Shackleton, Mark

Published
2021
Full Text
View/download PDF

21. Molecular Genomic Profiling of Melanocytic Nevi

Author

Colebatch, Andrew J., Ferguson, Peter, Newell, Felicity, Kazakoff, Stephen H., Witkowski, Tom, Dobrovic, Alexander, Johansson, Peter A., Saw, Robyn P.M., Stretch, Jonathan R., McArthur, Grant A., Long, Georgina V., Thompson, John F., Pearson, John V., Mann, Graham J., Hayward, Nicholas K., Waddell, Nicola, Scolyer, Richard A., and Wilmott, James S.

Published
2019
Full Text
View/download PDF

22. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

23. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Author

Valpione, Sara, Carlino, Matteo S., Mangana, Johanna, Mooradian, Meghan J., McArthur, Grant, Schadendorf, Dirk, Hauschild, Axel, Menzies, Alexander M., Arance, Ana, Ascierto, Paolo A., Di Giacomo, AnnaMaria, de Rosa, Francesco, Larkin, James, Park, John J., Goldinger, Simone M., Sullivan, Ryan J., Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael, Rai, Rajat, Gaba, Lydia, Long, Georgina V., and Lorigan, Paul

Published
2018
Full Text
View/download PDF

24. Future perspectives in melanoma research. Meeting report from the ¿Melanoma Bridge. Napoli, December 2nd-4th 2012¿

Author

Ascierto, Paolo A, Grimaldi, Antonio M, Acquavella, Nicolas, Borgognoni, Lorenzo, Calabrò, Luana, Cascinelli, Natale, Cesano, Alessandra, Del Vecchio, Michele, Eggermont, Alexander M, Faries, Mark, Ferrone, Soldano, Fox, Bernard A, Gajewski, Thomas F, Galon, Jérôme, Gnjatic, Sacha, Gogas, Helen, Kashani-Sabet, Mohammed, Kaufman, Howard L, Larkin, James, Lo, Roger S, Mantovani, Alberto, Margolin, Kim, Melief, Cornelis, McArthur, Grant, Palmieri, Giuseppe, Puzanov, Igor, Ribas, Antoni, Seliger, Barbara, Sosman, Jeff, Suenaert, Peter, Tarhini, Ahmad A, Trinchieri, Giorgio, Vidal-Vanaclocha, Fernando, Wang, Ena, Ciliberto, Gennaro, Mozzillo, Nicola, Marincola, Francesco M, and Thurin, Magdalena

Abstract

Abstract Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third “Melanoma Research: “A bridge from Naples to the World” meeting, shortened as “Bridge Melanoma Meeting” took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

Published
2013

27. Recombinant NY-ESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans

Author

Davis, Ian D., Chen, Weisan, Jackson, Heather, Parente, Phillip, Shackleton, Mark, Hopkins, Wendie, Chen, Qiyuan, Dimopoulos, Nektaria, Luke, Tina, Murphy, Roger, Scott, Andrew M., Maraskovsky, Eugene, McArthur, Grant, MacGregor, Duncan, Sturrock, Sue, Tai, Tsin Yee, Green, Simon, Cuthbertson, Andrew, Maher, Darryl, Miloradovic, Lena, Mitchell, Susan V., Ritter, Gerd, Jungbluth, Achim A., Chen, Yao-Tseng, Gnjatic, Sacha, Hoffman, Eric W., Old, Lloyd J., and Cebon, Jonathan S.

Published
2004

29. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Author

Hein, Nadine, Cameron, Donald P., Hannan, Katherine M., Nguyen, Nhu-Y N., Fong, Chun Yew, Sornkom, Jirawas, Wall, Meaghan, Pavy, Megan, Cullinane, Carleen, Diesch, Jeannine, Devlin, Jennifer R., George, Amee J., Sanij, Elaine, Quin, Jaclyn, Poortinga, Gretchen, Verbrugge, Inge, Baker, Adele, Drygin, Denis, Harrison, Simon J., Rozario, James D., Powell, Jason A., Pitson, Stuart M., Zuber, Johannes, Johnstone, Ricky W., Dawson, Mark A., Guthridge, Mark A., Wei, Andrew, McArthur, Grant A., Pearson, Richard B., and Hannan, Ross D.

Published
2017
Full Text
View/download PDF

31. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Author

Sanij, Elaine, Hannan, Katherine M., Xuan, Jiachen, Yan, Shunfei, Ahern, Jessica E., Trigos, Anna S., Brajanovski, Natalie, Son, Jinbae, Chan, Keefe T., Kondrashova, Olga, Lieschke, Elizabeth, Wakefield, Matthew J., Frank, Daniel, Ellis, Sarah, Cullinane, Carleen, Kang, Jian, Poortinga, Gretchen, Nag, Purba, Deans, Andrew J., Khanna, Kum Kum, Mileshkin, Linda, McArthur, Grant A., Soong, John, Berns, Els M. J. J., Hannan, Ross D., Scott, Clare L., Sheppard, Karen E., and Pearson, Richard B.

Published
2020
Full Text
View/download PDF

36. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Author

Ascierto, Paolo A, McArthur, Grant A, Dréno, Brigitte, Atkinson, Victoria, Liszkay, Gabrielle, Di Giacomo, Anna Maria, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Yan, Yibing, Wongchenko, Matthew, Chang, Ilsung, Hsu, Jessie J, Koralek, Daniel O, Rooney, Isabelle, Ribas, Antoni, and Larkin, James

Published
2016
Full Text
View/download PDF

40. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Author

McArthur, Grant A, Chapman, Paul B, Robert, Caroline, Larkin, James, Haanen, John B, Dummer, Reinhard, Ribas, Antoni, Hogg, David, Hamid, Omid, Ascierto, Paolo A, Garbe, Claus, Testori, Alessandro, Maio, Michele, Lorigan, Paul, Lebbé, Celeste, Jouary, Thomas, Schadendorf, Dirk, O'Day, Stephen J, Kirkwood, John M., Eggermont, Alexander M, Dréno, Brigitte, Sosman, Jeffrey A, Flaherty, Keith T, Yin, Ming, Caro, Ivor, Cheng, Suzanne, Trunzer, Kerstin, and Hauschild, Axel

Published
2014
Full Text
View/download PDF

46. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Author

Wolchok, Jedd D., Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, Lance C., Lao, Christopher D., Wagstaff, John, Schadendorf, Dirk, Ferrucci, Pier F., Smylie, Michael, Dummer, Reinhard, Hill, Andrew, Hogg, David, Haanen, John, Carlino, Matteo S., Bechter, Oliver, Maio, Michele, Marquez-Rodas, Ivan, Guidoboni, Massimo, McArthur, Grant, Lebbé, Celeste, Ascierto, Paolo A., Long, Georgina V., Cebon, Jonathan, Sosman, Jeffrey, Postow, Michael A., Callahan, Margaret K., Walker, Dana, Rollin, Linda, Bhore, Rafia, Hodi, Stephen F., and Larkin, James

Published
2017
Full Text
View/download PDF

49. Prospective comparison of volumetric post-contrast T1-Sampling Perfection with Application optimized Contrasts by using different flip angle Evolutions and Magnetization-Prepared Rapid Acquisition with Gradient Echo in patients with metastatic melanoma.

Author

Lasocki, Arian, Caspersz, Lauren, and McArthur, Grant A

Abstract

Introduction: Volumetric turbo spin echo (3D-TSE) T1-weighted imaging techniques such as T1-SPACE (Sampling Perfection with Application optimized Contrasts by using different flip angle Evolutions) improve detection of intracranial metastases (IM) compared to volumetric magnetisation-prepared gradient recalled echo techniques such as MPRAGE (Magnetization-Prepared Rapid Acquisition with Gradient Echo). However, incomplete vascular suppression can produce false positives when using 3D-TSE. Research into 3D-TSE has generally targeted patients with known or suspected IM, but the clinical implications of false positives are greater in patients with lower likelihood of IM. This study examined additional findings identified by T1-SPACE in patients with metastatic melanoma, targeting patients with a lower incidence of IM. Methods: Patients with metastatic melanoma and an upcoming brain MRI booking were identified prospectively. Consent for adding post-contrast T1-SPACE to the MRI protocol (which included MPRAGE) was obtained. Imaging was initially assessed without T1-SPACE. Subsequently, T1-SPACE images were examined and additional findings identified were recorded, including their correlation with MPRAGE. Results: One hundred examinations were performed, 24 having evidence of active IM. T1-SPACE allowed identification of additional lesions in five patients, including two with small solitary IM not identified when first assessing MPRAGE. In 18 examinations, T1-SPACE identified additional equivocal findings, confidently attributed to artefact (most commonly normal vessels) following correlation with MPRAGE. Conclusion: T1-SPACE improves detection of small lesions in patients without known IM, changing patient management. False positives are common but can be clarified with MPRAGE. Combining T1-SPACE and MPRAGE allows both sensitivity and specificity to be optimised. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results